K. Le Malicot

发表

miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial.

P. Laurent-Puig, C. Lepage, S. Martin-Lannerée, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)

C. Lepage, R. Guimbaud, C. Quantin, 2015, Health and Quality of Life Outcomes.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

D. Sargent, P. Laurent-Puig, R. Goldberg, 2017, JAMA oncology.

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.

M. Ducreux, O. Bouché, J. Taieb, 2021, European journal of cancer.

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial

J. Weitz, P. Laurent-Puig, F. Cianchi, 2019, Annals of Surgical Oncology.

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study

M. Loriot, P. Rougier, O. Bouché, 2015, Molecular Cancer Therapeutics.

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

C. Lepage, O. Bouché, C. Pétorin, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer.

C. Cheze-le Rest, P. Laurent-Puig, H. Sokol, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.

A. Hinke, G. Tortora, V. Boige, 2021, Cancer treatment reviews.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

C. Borel, C. Lepage, V. Boige, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

C. Lepage, J. Taieb, R. Coriat, 2020, European journal of cancer.

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.

T. de Baère, C. Lepage, G. Deplanque, 2020, Clinics and research in hepatology and gastroenterology.

Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials

P. Laurent-Puig, H. Blons, A. de Reyniès, 2021, British Journal of Cancer.

Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial

C. Lepage, N. Kerckhove, D. Pezet, 2022, BMC cancer.

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma

C. Lepage, J. Taieb, J. Bachet, 2022, The oncologist.

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

C. Lepage, V. Jooste, O. Bouché, 2022, European journal of cancer.

Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.

J. Ansquer, C. Foucher, R. Dalton, 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59

C. Lepage, D. Botsen, O. Bouché, 2022, Biomedicines.

Loss of SMARCB1 expression in colon carcinoma.

O. Delattre, C. Lepage, J. Mosnier, 2020, Cancer biomarkers : section A of Disease markers.

1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

A. Lièvre, C. Lepage, J. Scoazec, 2020 .

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

A. Lièvre, M. Ducreux, C. Lepage, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study.

B. Chauffert, C. Lepage, P. Maingon, 2014, European journal of cancer.

Fibrates and microvascular complications in diabetes--insight from the FIELD study.

J. Ansquer, C. Foucher, K. Le Malicot, 2009, Current pharmaceutical design.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

E. Baudin, C. Lepage, P. Rougier, 2017, European journal of cancer.

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.

A. Lièvre, C. Lepage, J. Scoazec, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Is it still time for meta-analyses in operable esophageal cancers, or rather for a change of paradigm?

K. Le Malicot, L. Bedenne, A. Drouillard, 2017, Journal of thoracic disease.

Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8.

D. Aust, R. Salazar, P. Laurent-Puig, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer

P. Laurent-Puig, C. Lepage, S. Coutant, 2022, Frontiers in Oncology.

Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2019, Journal of Clinical Oncology.

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

J. Taïeb, S. Olschwang, V. Boige, 2022, Therapeutic advances in medical oncology.

Prognostic value of the PrPC-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype

P. Laurent-Puig, S. Dedhar, J. Launay, 2021, Oncoimmunology.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer

P. Laurent-Puig, H. Blons, J. Launay, 2019, EBioMedicine.

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

D. Aust, R. Salazar, P. Laurent-Puig, 2021, Clinical Cancer Research.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study

C. Lepage, J. Emile, F. Ghiringhelli, 2019, Gut.

Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).

C. Lepage, R. Guimbaud, V. Boige, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2017, JAMA oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy

P. Laurent-Puig, J. Tabernero, C. Lepage, 2018, Clinical Cancer Research.

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

D. Sargent, F. Penault-Llorca, R. Goldberg, 2017, Journal of the National Cancer Institute.

The area between ROC curves, a non‐parametric method to evaluate a biomarker for patient treatment selection

Fabien Subtil, Muriel Rabilloud, Pierre Laurent-Puig, 2020, Biometrical journal. Biometrische Zeitschrift.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

P. Laurent-Puig, J. Tabernero, C. Lepage, 2016, JAMA oncology.

Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery

J. Blanc, B. Lapuyade, K. Le Malicot, 2021, Acta oncologica.

Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer

M. Abrahamowicz, V. Jooste, C. Quantin, 2021, BMC Medical Research Methodology.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

C. Reinhold, C. Borel, C. Lepage, 2019, Gut.

Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with a long term follow-up.

L. Quéro, C. Hennequin, A. Ruskoné-Fourmestraux, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

I. Sobhani, A. Lièvre, C. Lepage, 2022, Annals of Oncology.

Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.

I. Sobhani, A. Lièvre, C. Lepage, 2023, The Lancet. Oncology.

Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002

C. Mariette, G. Piessen, V. Christophe, 2013, BMC Cancer.

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

J. Taieb, J. Bachet, K. Le Malicot, 2018, British Journal of Cancer.

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

J. Taieb, J. Bachet, K. Le Malicot, 2018, British Journal of Cancer.

C. Mariette, G. Piessen, V. Christophe, 2013, BMC Cancer.

Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-ANABASE.

L. Quéro, A. Lièvre, C. Lepage, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

J. Ansquer, K. Le Malicot, C. Corda, 2009, Current therapeutic research, clinical and experimental.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

K. Le Malicot, C. Louvet, D. Tougeron, 2022, Annals of Oncology.

DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

R. Greil, R. Salazar, P. Laurent-Puig, 2016, JAMA oncology.

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial

A. Luciani, I. Sobhani, K. Leroy, 2015, BMC Cancer.

Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2020, JCO precision oncology.

"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".

C. Lepage, J. Emile, J. Taïeb, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2020, European Journal of Cancer.

Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.

R. Labianca, R. Goldberg, C. Lepage, 2022, European journal of cancer.

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

M. Loriot, J. Thariat, O. Bouché, 2019, Bulletin du cancer.

SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.

A. Lièvre, P. Laurent-Puig, C. Lepage, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial.

C. Lepage, V. Boige, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).

C. Lepage, F. Caroli-Bosc, J. Taieb, 2020, Clinical colorectal cancer.

A. Luciani, I. Sobhani, K. Leroy, 2015, BMC Cancer.

Adjuvant FOLFOX +/− cetuximab in full RAS and BRAF wildtype stage III colon cancer patients

P. Laurent-Puig, E. Van Cutsem, J. Tabernero, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

P. Laurent-Puig, F. Penault-Llorca, J. Tabernero, 2017, European journal of cancer.

Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: results of the FFCD 0904 phase II trial.

A. Lièvre, C. Lepage, X. Mirabel, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial

C. Lepage, R. Guimbaud, O. Bouché, 2018, Gastric Cancer.

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial.

C. Lepage, O. Bouché, D. Pezet, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens

X. Paoletti, R. Guimbaud, O. Bouché, 2023, ESMO open.

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).

V. Boige, O. Bouché, F. Ghiringhelli, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).

G. Piessen, O. Bouché, C. Eveno, 2019, Journal of Clinical Oncology.

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

C. Lombard-Bohas, A. Bertaut, F. Ghiringhelli, 2020, Cancers.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

P. Laurent-Puig, F. Penault-Llorca, J. Tabernero, 2017, European journal of cancer.

Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3)

C. Lepage, C. Pétorin, T. Mazard, 2024, Clinical and translational radiation oncology.

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial.

P. Laurent-Puig, E. Assenat, M. Levrero, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.

C. Lemanski, K. Le Malicot, D. Tougeron, 2024, British journal of cancer.